Compare
Ginkgo Bioworks Holdings, Inc. vs REGENXBIO Inc. vs Beam Therapeutics Inc. vs Vaxart, Inc.
| Latest fiscal year | Ginkgo Bioworks Holdings, Inc. DNA | REGENXBIO Inc. RGNX | Beam Therapeutics Inc. BEAM | Vaxart, Inc. VXRT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $170.16M | $170.44M | $139.74M | $237.26M |
| Revenue growth (YoY) | -25.1% | +104.5% | +120.0% | +726.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -185.3% | -94.6% | -274.6% | 7.6% |
| Net margin | -183.8% | -113.8% | -57.2% | 6.9% |
| Net income | -$312.76M | -$193.88M | -$79.99M | $16.33M |
| EPS (Diluted) | -$5.64 | -$3.76 | -$0.81 | $0.07 |
| Operating cash flow | -$171.06M | -$123.96M | -$345.10M | $7.71M |
| Free cash flow | -$178.72M | -$126.38M | -$360.05M | $7.57M |
| Cash & equivalents | $167.20M | $34.47M | $294.94M | n/a |
| Total assets | $1.12B | $453.03M | $1.48B | $186.08M |
| Total liabilities | $611.11M | $350.30M | $242.82M | $98.28M |
| Shareholders' equity | $508.59M | $102.73M | $1.24B | $87.80M |
| Return on year-end equity | -61.5% | -188.7% | -6.5% | 18.6% |
| Shares outstanding | 58.21M | 50.89M | 101.75M | 240.49M |
Revenue, most recent five fiscal years
| Fiscal year | Ginkgo Bioworks Holdings, Inc. | REGENXBIO Inc. | Beam Therapeutics Inc. | Vaxart, Inc. |
|---|---|---|---|---|
| Latest | $170.16M Ended 2025-12-31 | $170.44M Ended 2025-12-31 | $139.74M Ended 2025-12-31 | $237.26M Ended 2025-12-31 |
| 1 year earlier | $227.04M Ended 2024-12-31 | $83.33M Ended 2024-12-31 | $63.52M Ended 2024-12-31 | $28.70M Ended 2024-12-31 |
| 2 years earlier | $251.46M Ended 2023-12-31 | $90.24M Ended 2023-12-31 | $377.71M Ended 2023-12-31 | $7.38M Ended 2023-12-31 |
| 3 years earlier | $477.71M Ended 2022-12-31 | $112.72M Ended 2022-12-31 | $60.92M Ended 2022-12-31 | $107.0K Ended 2022-12-31 |
| 4 years earlier | $313.84M Ended 2021-12-31 | $470.35M Ended 2021-12-31 | $51.84M Ended 2021-12-31 | $892.0K Ended 2021-12-31 |